15 patients with remitting-progressive multiple sclerosis received a course of intravenous cyclophosphamide followed by a booster dose every 60 days for 2 years. There were no severe short or medium term side effects. Half of the patients presented clinical stabilization and substantially unchanged Kurtzke rating at 2 year follow-up. Since the aim was stabilization only, our findings argue for continuation of the study in young patients with very short shift.

15 pazienti affetti da sclerosi multipla remittente-progressiva, sono stati sottoposti a ciclo di CTX endovena con richiami ogni sessanta giorni. Non ci sono stati pesanti effetti collaterali a breve e medio termine. A due anni di follow-up il 50% dei pazienti ha mostrato una stabilizzazione della malattia.